International Stem Cell (ISCO) versus Its Rivals Head to Head Contrast

International Stem Cell (OTCMKTS: ISCO) is one of 531 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its rivals? We will compare International Stem Cell to similar businesses based on the strength of its valuation, analyst recommendations, dividends, earnings, profitability, risk and institutional ownership.

Valuation & Earnings

This table compares International Stem Cell and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
International Stem Cell $7.46 million -$6.06 million -1.09
International Stem Cell Competitors $2.18 billion $164.73 million -1.85

International Stem Cell’s rivals have higher revenue and earnings than International Stem Cell. International Stem Cell is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares International Stem Cell and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
International Stem Cell -23.26% -123.16% -31.68%
International Stem Cell Competitors -1,917.64% -92.21% -26.21%

Institutional & Insider Ownership

46.8% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 83.2% of International Stem Cell shares are owned by insiders. Comparatively, 15.0% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk & Volatility

International Stem Cell has a beta of -0.24, indicating that its stock price is 124% less volatile than the S&P 500. Comparatively, International Stem Cell’s rivals have a beta of 1.16, indicating that their average stock price is 16% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for International Stem Cell and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
International Stem Cell 0 0 0 0 N/A
International Stem Cell Competitors 3865 11249 25488 850 2.56

As a group, “Pharmaceutical preparations” companies have a potential upside of 59.65%. Given International Stem Cell’s rivals higher probable upside, analysts clearly believe International Stem Cell has less favorable growth aspects than its rivals.

Summary

International Stem Cell rivals beat International Stem Cell on 7 of the 10 factors compared.

International Stem Cell Company Profile

International Stem Cell Corporation focuses on the development of therapeutic and biomedical products worldwide. The company's products are based on human parthenogenetic stem cells, a proprietary type of pluripotent stem cell. It develops various cell types, including neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; liver cells to treat various congenital and acquired liver diseases; and islet cells for the treatment of diabetes. The company also develops, manufactures, and markets skincare products and human cell culture products. Its human cell culture products include human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. The company's human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; human female reproductive system cells for the study of cellular physiology; human skeletal muscle cells for the study of biology, diabetes, insulin receptor studies, muscle metabolism, muscle tissue repair, and myotube development; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. It sells skincare products through a Website and professional channels; and human cell culture products through its sales force, OEM partners, and brand distributors. The company was founded in 2001 and is headquartered in Carlsbad, California.

Receive News & Ratings for International Stem Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for International Stem Cell and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit